Your pathway to relevant Publications and Guidelines on breast cancer management
The guidelines
Link to the latest breast cancer treatment guidelines issued by:
The publications
Find out what clinical investigators are saying about FEMARA®.
New England Journal of Medicine ePrint of the Big 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med, August 2009.
Crivellari et al. Letrozole compared with tamoxifen for elderly patients with endocrine responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol, April 2008.
Gluck S. The prevention and management of distant metastases in women with breast cancer. Cancer Invest, January 2007.
Mouridsen HT. Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat, February 2007. [Epub ahead of print]
New England Journal of Medicine ePrint of the Big 1-98 Collaborative Group A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer. N Engl J Med, December 2005.
Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med, November 2003.
To read about the significant benefits of FEMARA® in the initial adjuvant setting, click here.
FEMARA® is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
